Srdan Verstovsek, MD, on Predicting Resistance to Hydroxyurea Therapy in Polycythemia Vera
By Leah Sherwood, Srdan Verstovsek, MD, PhD - Last Updated: December 20, 2022Srdan Verstovsek, MD, of the MD Anderson Cancer Center, speaks on a study that used machine learning to predict resistance to hydroxyurea therapy in patients with polycythemia vera. Dr. Verstovsek and colleagues presented the study’s results at the 2022 American Society of Hematology Annual Meeting.
Post Tags:ASH22
Advertisement
Related Posts
Dr. Zeidan speaks about the rationale behind the trial, the implications of its results, and the next steps.
Dr. Venugopal, who was not involved in the study, discusses the results and implications of the phase III trial.
Dr. Hill and colleagues presented their research on the CAR-T manufacturing approach during the 2023 ASCO meeting.
Health care disparities have been an "ongoing issue" for patients with cancer, especially in multiple myeloma.
At the ASCO meeting, researchers presented results of the trial with 22 months of follow-up.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
670 Madison Ave.
Manalapan, NJ 07726